Effects of Hydrogen Inhalation on Neurological Function Indicators, Oxidative Stress Markers, and E-Cadherin Levels in Patients with Brain Glioma.
Yan Li, Li Zhang, Shengjun Wang, Yumin Feng, Zhiyin Pang, Wenjian Zhen, Jinmin Hao · Alternative therapies in health and medicine · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 100 patients with brain glioma, similarly, S100β, NSE, GFAP, and MDA levels were found to be lower in the hydrogen group (0.41±0.09 μg/L, 8.24±1.64 ng/mL, 0.71±0.23 pg/mL, and 6.05±1.08 mmol/L respectively) than in the routine group (0.66±0.12 μg/L, 10.67±1.83 ng/mL, 0.93±0.29 pg/mL, and 7.21±1.12 mmol/L respectively) with P <.05 for all comparisons. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 100 patients with brain glioma. Similarly, S100β, NSE, GFAP, and MDA levels were found to be lower in the hydrogen group (0.41±0.09 μg/L, 8.24±1.64 ng/mL, 0.71±0.23 pg/mL, and 6.05±1.08 mmol/L respectively) than in the routine group (0.66±0.12 μg/L, 10.67±1.83 ng/mL, 0.93±0.29 pg/mL, and 7.21±1.12 mmol/L respectively) with P <.05 for all comparisons.
What the Researchers Studied
The researchers studied 100 patients with brain glioma. The study used a randomized human clinical trial.
What Effects Did Molecular Hydrogen Have?
100 glioma patients were enrolled and divided into two groups using the random number table: routine treatment (50) and hydrogen inhalation plus routine treatment (50). Similarly, S100β, NSE, GFAP, and MDA levels were found to be lower in the hydrogen group (0.41±0.09 μg/L, 8.24±1.64 ng/mL, 0.71±0.23 pg/mL, and 6.05±1.08 mmol/L respectively) than in the routine group (0.66±0.12 μg/L, 10.67±1.83 ng/mL, 0.93±0.29 pg/mL, and 7.21±1.12 mmol/L respectively) with P <.05 for all comparisons.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 100 patients with brain glioma. The study used a randomized human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.